SET2 is a drug which acts as a selective antagonist for the TRPV2 receptor. It is moderately potent with an IC<sub>50</sub> of 460nM, but is highly selective for TRPV2 over the other subtypes of TRPV, and is the first such compound to be developed. A role has been suggested for TRPV2 in tumor metastasis, making this a target of interest in the treatment of cancer.